Expression of glucagon-like peptide-1 receptor and glucose‑dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells

Aoyama,Emina; Watari,Ippei; Podyma-Inoue,Katarzyna   Anna; Yanagishita,Masaki; Ono,Takashi

doi:10.3892/ijmm.2014.1787

Expression of glucagon-like peptide-1 receptor and glucose‑dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells

Authors:
- Emina Aoyama
- Ippei Watari
- Katarzyna Anna Podyma-Inoue
- Masaki Yanagishita
- Takashi Ono
View Affiliations

Affiliations: Department of Orthodontic Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo 113-8549, Japan, Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo 113-8549, Japan
Published online on: May 27, 2014 https://doi.org/10.3892/ijmm.2014.1787
Pages: 475-482

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP‑1R) are incretin receptors that play important roles in regulating insulin secretion from pancreatic β cells. Incretin receptors are also thought to play a potential role in bone metabolism. Osteoblasts in animals and humans express GIPR; however, the presence of GLP-1R in these cells has not been reported to date. Thus, the aim of this study was to determine whether GLP-1R and GIPR are expressed in osteoblastic cells, and whether their expression levels are regulated by the extracellular glucose concentration. Mouse osteoblastic MC3T3-E1 cells were cultured in medium containing normal (5.6 mM) or high (10, 20 or 30 mM) glucose concentrations, with or without bone morphogenetic protein-2 (BMP-2). RT-PCR, western blot analysis and immunofluorescence were carried out to determine GIPR and GLP-1R mRNA and protein expression levels. Cell proliferation was also assessed. The GLP-1R and GIPR mRNA expression levels were higher in the MC3T3-E1 cells cultured in medium containing high glucose concentrations with BMP-2 compared with the cells cultured in medium containing normal glucose concentrations with or without BMP-2. GLP-1R protein expression increased following culture in high-glucose medium with BMP-2 compared with culture under normal glucose conditions. However, the cellular localization of GLP-1R was not affected by either glucose or BMP-2. In conclusion, our data demonstrate that the expression of GLP-1R and GIPR is regulated by glucose concentrations in MC3T3-E1 cells undergoing differentiation induced by BMP-2. Our results reveal the potential role of incretins in bone metabolism.

View Figures

View References

1	Perry T and Greig NH: Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer’s disease. Curr Alzheimer Res. 2:377–385. 2005.PubMed/NCBI
2	Lavin JH, Wittert GA, Andrews J, et al: Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate. Am J Clin Nutr. 68:591–598. 1998.PubMed/NCBI
3	Nikolaidis LA, Elahi D, Hentosz T, et al: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 110:955–961. 2004. View Article : Google Scholar
4	Dupre J, Behme MT, Hramiak IM, et al: Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes. 44:626–630. 1995. View Article : Google Scholar : PubMed/NCBI
5	Ding KH, Zhong Q, Xie D, et al: Effects of glucose-dependent insulinotropic peptide on behavior. Peptides. 27:2750–2755. 2006. View Article : Google Scholar : PubMed/NCBI
6	Miyawaki K, Yamada Y, Ban N, et al: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 8:738–742. 2002. View Article : Google Scholar : PubMed/NCBI
7	Gaudin-Audrain C, Irwin N, Mansur S, et al: Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone. 53:221–230. 2013.PubMed/NCBI
8	Ceccarelli E, Guarino EG, Merlotti D, et al: Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. Front Endocrinol (Lausanne). 4:732013.PubMed/NCBI
9	Hansotia T and Drucker DJ: GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept. 128:125–134. 2005. View Article : Google Scholar : PubMed/NCBI
10	Yip RG, Boylan MO, Kieffer TJ and Wolfe MM: Functional GIP receptors are present on adipocytes. Endocrinology. 139:4004–4007. 1998. View Article : Google Scholar : PubMed/NCBI
11	Seino Y, Fukushima M and Yabe D: GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest. 1:8–23. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ferron M, Wei J, Yoshizawa T, et al: Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 142:296–308. 2010. View Article : Google Scholar : PubMed/NCBI
13	Kamada A, Ikeo T, Yoshikawa Y, et al: Gene expression of adipocytokine receptors during osteoblastic differentiation. J Oral Tissue Eng. 7:53–60. 2009.
14	Huang CY, Lee CY, Chen MY, Tsai HC, Hsu HC and Tang CH: Adiponectin increases BMP-2 expression in osteoblasts via AdipoR receptor signaling pathway. J Cell Physiol. 224:475–483. 2010. View Article : Google Scholar : PubMed/NCBI
15	Prigeon RL, Quddusi S, Paty B and D’Alessio DA: Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab. 285:E701–E707. 2003.PubMed/NCBI
16	Sancho V, Nuche B, Arnés L, et al: The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. Int J Mol Med. 19:961–966. 2007.PubMed/NCBI
17	Vella A, Shah P, Reed AS, Adkins AS, Basu R and Rizza RA: Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia. 45:1410–1415. 2002.PubMed/NCBI
18	Egan JM, Meneilly GS, Habener JF and Elahi D: Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab. 87:3768–3773. 2002. View Article : Google Scholar : PubMed/NCBI
19	Nuche-Berenguer B, Moreno P, Esbrit P, et al: Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int. 84:453–461. 2009. View Article : Google Scholar : PubMed/NCBI
20	Yamada C, Yamada Y, Tsukiyama K, et al: The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 149:574–579. 2008. View Article : Google Scholar : PubMed/NCBI
21	Bollag RJ, Zhong Q, Phillips P, et al: Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology. 141:1228–1235. 2000.PubMed/NCBI
22	Zhong Q, Itokawa T, Sridhar S, et al: Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 292:E543–E548. 2007. View Article : Google Scholar : PubMed/NCBI
23	Xie D, Cheng H, Hamrick M, et al: Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone. 37:759–769. 2005. View Article : Google Scholar : PubMed/NCBI
24	Mieczkowska A, Irwin N, Flatt PR, Chappard D and Mabilleau G: Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone. 56:337–342. 2013. View Article : Google Scholar : PubMed/NCBI
25	Noguchi H, Oishi K, Ueda M, et al: Establishment of mouse pancreatic stem cell line. Cell Transplant. 18:563–571. 2009.PubMed/NCBI
26	Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
27	Nuche-Berenguer B, Portal-Núñez S, Moreno P, et al: Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 225:585–592. 2010. View Article : Google Scholar : PubMed/NCBI
28	Lamari Y, Boissard C, Moukhtar MS, Jullienne A, Rosselin G and Garel JM: Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett. 393:248–252. 1996. View Article : Google Scholar : PubMed/NCBI
29	Tsukiyama K, Yamada Y, Yamada C, et al: Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol. 20:1644–1651. 2006. View Article : Google Scholar : PubMed/NCBI
30	Ambrosio ML, Monami M, Sati L, Marchionni N, Di Bari M and Mannucci E: GLP-1 receptor agonist-induced polyarthritis: a case report. Acta Diabetol. Oct 25–2013.(Epub ahead of print).
31	Russell JW, Sullivan KA, Windebank AJ, Herrmann DN and Feldman EL: Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis. 6:347–363. 1999. View Article : Google Scholar : PubMed/NCBI
32	Romeo G, Liu WH, Asnaghi V, Kern TS and Lorenzi M: Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes. 51:2241–2248. 2002. View Article : Google Scholar : PubMed/NCBI
33	Piconi L, Quagliaro L, Assaloni R, et al: Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 22:198–203. 2006. View Article : Google Scholar : PubMed/NCBI
34	Weil BR, Abarbanell AM, Herrmann JL, Wang Y and Meldrum DR: High glucose concentration in cell culture medium does not acutely affect human mesenchymal stem cell growth factor production or proliferation. Am J Physiol Regul Integr Comp Physiol. 296:R1735–R1743. 2009. View Article : Google Scholar : PubMed/NCBI
35	Balint E, Szabo P, Marshall CF and Sprague SM: Glucose-induced inhibition of in vitro bone mineralization. Bone. 28:21–28. 2001. View Article : Google Scholar : PubMed/NCBI
36	Yabe D and Seino Y: Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation. Prog Biophys Mol Biol. 107:248–256. 2011.
37	Pedersen J, Ugleholdt RK, Jørgensen SM, et al: Glucose metabolism is altered after loss of L cells and alpha-cells but not influenced by loss of K cells. Am J Physiol Endocrinol Metab. 304:E60–E73. 2013. View Article : Google Scholar : PubMed/NCBI
38	Choi KY, Kim HJ, Lee MH, et al: Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. Dev Dyn. 233:115–121. 2005. View Article : Google Scholar : PubMed/NCBI
39	Gigoux V and Fourmy D: Acting on hormone receptors with minimal side effect on cell proliferation: A timely challenge illustrated with GLP-1R and GPER. Front Endocrinol (Lausanne). 4:502013.PubMed/NCBI
40	Monami M, Cresci B, Colombini A, et al: Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care. 31:199–203. 2008. View Article : Google Scholar : PubMed/NCBI
41	Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H and Meier CR: Use of thiazolidinediones and fracture risk. Arch Intern Med. 168:820–825. 2008. View Article : Google Scholar : PubMed/NCBI
42	Bazelier MT, Gallagher AM, van Staa TP, et al: Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiol Drug Saf. 21:507–514. 2012. View Article : Google Scholar : PubMed/NCBI
43	Monami M, Dicembrini I, Antenore A and Mannucci E: Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 34:2474–2476. 2011. View Article : Google Scholar
44	Drucker DJ and Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidase-4 inhibitors in type 2 diabetes. Lancet. 368:1696–1705. 2006. View Article : Google Scholar : PubMed/NCBI
45	Tahara N, Yamagishi S, Takeuchi M, et al: Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clin Biochem. 46:300–303. 2013. View Article : Google Scholar : PubMed/NCBI
46	Yamagishi S and Matsui T: Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des. 17:4379–4385. 2011. View Article : Google Scholar : PubMed/NCBI